Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.58 |
| ▸ | HTR2A | P28223 | 3/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 2/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
| ▸ | HTR6 | P50406 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MC5R | P33032 | 1/20 | 0.52 |
| ▸ | MC3R | P41968 | 1/20 | 0.52 |
| ▸ | MC1R | Q01726 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Serdemetan SCHEMBL3012498 | 1.00 | HRH3 (0.58) | HRH3HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL12782483 | 0.92 | HDAC3 (0.56) | HRH3HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL12845524 | 0.91 | HDAC3 (0.53) | HRH3HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL12782284 | 0.89 | HRH3 (0.61) | HRH3HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL12845514 | 0.88 | HRH3 (0.54) | HRH3HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL12845676 | 0.88 | PTGS2 (0.62) | HRH3HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL8041023 | 0.87 | KMT2A (0.53) | HTR2AHTR1ADRD2HTR7HTR6 | |
| SCHEMBL12845346 | 0.87 | HRH3 (0.59) | HRH3HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL8043532 | 0.87 | KMT2A (0.54) | HRH3HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL12845369 | 0.86 | HRH3 (0.54) | HRH3KMT2AMEN1HTTMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3947736-B1 | PROGNOSIS METHOD OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2026-03-11 | — | — | EP | claimed |
| US-20250312353-A1 | DRUG REPURPOSING FOR TREATMENT OF CONGENITAL VASCULAR MALFORMATIONS | UNIVERSITY OF SOUTH CAROLINA (US) | 2025-10-09 | — | — | US | claimed |
| US-20250127777-A1 | DUAL INHIBITION OF MDM2 AND EIF2-ALPHA INDUCES CELL DEATH IN MULTIPLE CANCER CELL TYPES | UNIV COLORADO REGENTS (US) | 2025-04-24 | — | — | US | claimed |
| US-20250049815-A1 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR TO AMELIORIATE VASCULAR STIFFNESS | BUCK INST RES AGING (US) | 2025-02-13 | — | — | US | claimed |
| WO-2024196963-A2 | COMPOSITIONS AND METHODS FOR GENOME EDITING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-09-26 | — | — | WO | claimed |
| US-20240299558-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-09-12 | — | — | US | claimed |
| EP-4380574-A2 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR TO AMELIORIATE VASCULAR STIFFNESS | Buck Institute for Research on Aging (US) | 2024-06-12 | — | — | EP | claimed |
| WO-2024006252-A1 | DUAL INHIBITION OF MDM2 AND EIF2-ALPHA INDUCES CELL DEATH IN MULTIPLE CANCER CELL TYPES | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2024-01-04 | — | — | WO | claimed |
| CN-117017987-A | Pharmaceutical composition for preventing and treating lung cancer, and preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2023-11-10 | — | — | CN | claimed |
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-11-02 | — | — | US | claimed |
| CN-116510024-A | Composition, preparation method and application thereof | 上海复东生物医药有限责任公司 | 2023-08-01 | — | — | CN | claimed |
| EP-4157204-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | Buck Institute for Research on Aging (US) | 2023-04-05 | — | — | EP | claimed |
| WO-2023014718-A2 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR TO AMELIORIATE VASCULAR STIFFNESS | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2023-02-09 | — | — | WO | claimed |
| US-20230027472-A1 | TARGETING P73 FOR CANCERS RESISTANT TO BH3 MIMETICS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-01-26 | — | — | US | claimed |
| WO-2022266491-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-12-22 | — | — | WO | claimed |
| US-11471462-B2 | Compositions and methods for detecting and treating diabetes | THE BROAD INSTITUTE, INC. (US) | 2022-10-18 | — | — | US | claimed |
| US-20220186321-A1 | PROGNOSIS METHOD OF CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-06-16 | — | — | US | claimed |
| EP-3947736-A1 | PROGNOSIS METHOD OF CANCER | Centre national de la recherche scientifique (FR) | 2022-02-09 | — | — | EP | claimed |
| US-20220031694-A1 | COMBINATION PRODUCT OF BCL-2 INHIBITOR AND MDM2 INHIBITOR AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-02-03 | — | — | US | claimed |
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | disclosed |
| US-12599592-B2 | Therapeutic small molecules for treatment of pulmonary hypertension | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4719409-A1 | TREATMENT OF ENDOMETRIAL CANCER WITH MDM2 INHIBITORS | Kartos Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12595515-B2 | Prognosis method of cancer | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2026-04-07 | — | — | US | disclosed |
| EP-3947736-B1 | PROGNOSIS METHOD OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2026-03-11 | — | — | EP | disclosed |
| CN-121586709-A | Checkpoint kinase 1 (CHK 1) inhibitor crystal forms and uses thereof | 无界生物公司 | 2026-02-27 | — | — | CN | disclosed |
| EP-4688770-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITOR CRYSTALLINE FORM AND USES THEREOF | Boundless Bio, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4683635-A1 | USES OF A CHECKPOINT KINASE 1 (CHK1) INHIBITOR | Boundless Bio, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SCIPHER MEDICINE CORP (US) | 2026-01-22 | — | — | US | disclosed |
| US-12527790-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | BOUNDLESS BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4676602-A1 | COMPOUNDS TARGETING MUTATIONS IN P53 AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250388602-A1 | Tetrahydropyranopyrazole Derivatives for the Treatment of Cancer and Viral Infections | GENASE THERAPEUTICS B V (NL) | 2025-12-25 | — | — | US | disclosed |
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4653052-A2 | TREATMENT OF CANCER HAVING GNAQ OR GNA11 GENETIC MUTATIONS WITH PROTEIN KINASE C INHIBITORS | Ideaya Biosciences, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250354117-A1 | METHODS OF GENERATING NATURAL KILLER CELLS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF | CHILDRENS MEDICAL CT CORP (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2025227060-A1 | HETEROCYCLIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) IN COMBINATION WITH ADDITIONAL AGENTS FOR USE IN THE TREATMENT OF CANCER | INSILICO MEDICINE IP LIMITED (CN) | 2025-10-30 | — | — | WO | disclosed |
| CN-117017987-B | Pharmaceutical composition for preventing and treating lung cancer, and preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2025-10-21 | — | — | CN | disclosed |
| EP-4629993-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | Kartos Therapeutics (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-4469461-B1 | TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS | GENASE THERAPEUTICS B V (NL) | 2025-10-15 | — | — | EP | disclosed |
| US-20250312353-A1 | DRUG REPURPOSING FOR TREATMENT OF CONGENITAL VASCULAR MALFORMATIONS | UNIVERSITY OF SOUTH CAROLINA (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4626433-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS COMBINATIONS AND USES THEREOF | Boundless Bio, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20250288572-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY VASCULAR DISEASE | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2025-09-18 | — | — | US | disclosed |
| EP-4606433-A2 | FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS | Sumitomo Pharma America, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250236841-A1 | METHODS TO ENHANCE TUMOR IMMUNOGENICITY AND COMPOSITIONS FOR AUTOLOGOUS CANCER IMMUNOTHERAPEUTIC PRODUCTS USING MODIFIED TUMOR CELLS AND MODIFIED DENDRITIC CELLS | AIVITA BIOMEDICAL INC (US) | 2025-07-24 | — | — | US | disclosed |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | ARRAY BIOPHARMA INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-12350247-B2 | Use of APE1/Ref-1 inhibitors for treatment of retinal diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| EP-3908282-B1 | TREATMENT OF CANCER HAVING GNAQ OR GNA11 GENETIC MUTATIONS WITH PROTEIN KINASE C INHIBITORS | IDEAYA BIOSCIENCES INC (US) | 2025-07-02 | — | — | EP | disclosed |
| CN-120037232-A | Methods of treating cancer | 卡托斯医疗公司 | 2025-05-27 | — | — | CN | disclosed |
| WO-2025106804-A1 | COMPOSITIONS AND METHODS FOR CHARACTERIZING HEPATOCYTE STRESS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-3474849-B1 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING DIABETES | BROAD INST INC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-3924351-B1 | CRYSTALLINE FORM OF THE HYDROCHLORIDE SALT OF 2-((1R,4R)-4-((3-(3-(TRIFLUOROMETHYL)PHENYL) IMIDAZO[1,2-B]PYRIDAZIN-6-YL)AMINO)CYCLOHEXYL)PROPAN-2-OL | SUMITOMO PHARMA AMERICA INC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20250134876-A1 | METHODS OF TREATING A CANCER OVEREXPRESSING ONE OR MORE BCL-2 FAMILY PROTEINS | KARTOS THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250134877-A1 | METHODS OF TREATING CANCER DEPENDENT ON MYC GENE EXPRESSSION | KARTOS THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| US-12285427-B2 | Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL selective inhibitor | UNITY BIOTECHNOLOGY, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250127777-A1 | DUAL INHIBITION OF MDM2 AND EIF2-ALPHA INDUCES CELL DEATH IN MULTIPLE CANCER CELL TYPES | UNIV COLORADO REGENTS (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025076057-A1 | SELECTIVE INHIBITION OF MDM2-AMPLIFIED CANCERS USING TARGETED PROTEIN DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| EP-4532486-A1 | PYRIDINE CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | Boundless Bio, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | KARTOS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250090517-A1 | Methods of Treating Cancer | KARTOS THERAPEUTICS INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-20250078957-A1 | Unsupervised Machine Learning Methods | AMPEL BIOSOLUTIONS LLC (US) | 2025-03-06 | — | — | US | disclosed |
| CN-119546588-A | Pyridine checkpoint kinase 1 (CHK 1) inhibitors and uses thereof | 无界生物公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20250049815-A1 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR TO AMELIORIATE VASCULAR STIFFNESS | BUCK INST RES AGING (US) | 2025-02-13 | — | — | US | disclosed |
| US-20250025484-A1 | POLYMERSOME NANOPARTICLES EXHAUSTING INTRACELLUAR AMINO ACID FOR CANCER THERAPY AND METHODS THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2025-01-23 | — | — | US | disclosed |
| US-20250022541-A1 | Unsupervised Machine Learning Methods | AMPEL BIOSOLUTIONS LLC (US) | 2025-01-16 | — | — | US | disclosed |
| US-12194031-B2 | Compounds for use in regulating follicle maturation | AARHUS UNIVERSITET (DK) | 2025-01-14 | — | — | US | disclosed |
| WO-2025007955-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2025-01-09 | — | — | WO | disclosed |
| US-20240428948-A1 | Unsupervised Machine Learning Methods | AMPEL BIOSOLUTIONS LLC (US) | 2024-12-26 | — | — | US | disclosed |
| EP-4479973-A1 | UNSUPERVISED MACHINE LEARNING METHODS | Ampel Biosolutions, LLC (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2024254156-A1 | TREATMENT OF ENDOMETRIAL CANCER WITH MDM2 INHIBITORS | KARTOS THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| EP-4469461-A1 | TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS | Genase Therapeutics B.V. (NL) | 2024-12-04 | — | — | EP | disclosed |
| EP-4129285-B1 | COMPOUNDS FOR USE IN REGULATING FOLLICLE MATURATION | UNIV AARHUS (DK) | 2024-11-20 | — | — | EP | disclosed |
| US-12138250-B2 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | LOXO ONCOLOGY, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| CN-118946568-A | Tetrahydropyranopyrazole derivatives for the treatment of cancer and viral infections | 格纳赛治疗有限公司 | 2024-11-12 | — | — | CN | disclosed |
| WO-2024229262-A1 | NARROW-SPECTRUM ANTIBIOTIC COMPOUNDS AND USES THEREOF | MCMASTER UNIVERSITY (CA) | 2024-11-07 | — | — | WO | disclosed |
| US-20240363249-A1 | Machine Learning Disease Prediction and Treatment Prioritization | AMPEL BIOSOLUTIONS, LLC | 2024-10-31 | — | — | US | disclosed |
| US-20240360135-A1 | IMIDAZO[1,2-B]PYRIDAZINYL COMPOUNDS AND USES THEREOF | SUMITOMO PHARMA ONCOLOGY INC (US) | 2024-10-31 | — | — | US | disclosed |
| WO-2024217502-A1 | METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITOR COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-10-24 | — | — | WO | disclosed |
| US-12115153-B2 | Methods of treating cancer | KARTOS THERAPEUTICS, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240336977-A1 | MICRORNA-REGULATED BIOMARKERS AND DRUG TARGETS FOR IMPROVING DIAGNOSIS AND TREATMENT OF LUNG OR BREAST CANCER | West Virginia University Board of Governors on behalf of West Virginia University (US) | 2024-10-10 | — | — | US | disclosed |
| WO-2024211270-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITOR CRYSTALLINE FORM AND USES THEREOF | BOUNDLESS BIO, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| WO-2024211271-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITOR PHARMACEUTICAL COMPOSITION | BOUNDLESS BIO, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20240327435-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. | 2024-10-03 | — | — | US | disclosed |
| US-12102621-B2 | Formulations of 6-(2-hydroxy-methylpropoxy-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | LOXO ONCOLOGY, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| WO-2024196963-A2 | COMPOSITIONS AND METHODS FOR GENOME EDITING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-09-26 | — | — | WO | disclosed |
| WO-2024196923-A1 | USES OF A CHECKPOINT KINASE 1 (CHK1) INHIBITOR | BOUNDLESS BIO, INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| US-20240307414-A1 | METHODS AND MATERIALS FOR TREATING PROSTATE CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2024-09-19 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| US-20240299558-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-09-12 | — | — | US | disclosed |
| WO-2024187153-A1 | COMPOUNDS TARGETING MUTATIONS IN P53 AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20240293364-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-09-05 | — | — | US | disclosed |
| CN-118459485-A | Amino-substituted heterocycles for the treatment of cancers with EGFR mutations | 纽威伦特公司 | 2024-08-09 | — | — | CN | disclosed |
| EP-4398903-A1 | METHODS OF TREATING CANCER DEPENDENT ON MYC GENE EXPRESSION | Kartos Therapeutics (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-4398905-A1 | METHODS OF TREATING A CANCER OVEREXPRESSING ONE OR MORE BCL-2 FAMILY PROTEINS | Kartos Therapeutics (US) | 2024-07-17 | — | — | EP | disclosed |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-118319866-A | Formulations comprising RET kinase inhibitors | 罗索肿瘤学公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | BUCK INST RES AGING (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240203555-A1 | METHODS AND SYSTEMS FOR THERAPY MONITORING AND TRIAL DESIGN | SCIPHER MEDICINE CORP (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240197729-A1 | ALK-5 Inhibitors and Uses Thereof | SUMITOMO PHARMA ONCOLOGY INC (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024124240-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS (US) | 2024-06-13 | — | — | WO | disclosed |
| EP-4380574-A2 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR TO AMELIORIATE VASCULAR STIFFNESS | Buck Institute for Research on Aging (US) | 2024-06-12 | — | — | EP | disclosed |
| WO-2024118596-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS COMBINATIONS AND USES THEREOF | BOUNDLESS BIO, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024118564-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-11980616-B2 | Treating liver disease by selectively eliminating senescent cells | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240153580-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | Scipher Medicine Corporation | 2024-05-09 | — | — | US | disclosed |
| US-20240145038-A1 | cfDNA FRAGMENTOMIC DETECTION OF CANCER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-05-02 | — | — | US | disclosed |
| US-11963950-B2 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | LOXO ONCOLOGY INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-11963957-B2 | Treating cardiovascular disease by selectively eliminating senescent cells | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-04-23 | — | — | US | disclosed |
| US-11964988-B2 | Fused heterocyclic compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240115563-A1 | Treatment of a Senescence-Associated Ocular Disease or Disorder Using a Bcl-xL Selective Inhibitor | UNITY BIOTECHNOLOGY, INC. | 2024-04-11 | — | — | US | disclosed |
| US-20240118266-A1 | CELL DEATH BIOMARKER | UCL BUSINESS PLC (GB) | 2024-04-11 | — | — | US | disclosed |
| EP-4347582-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | Boundless Bio, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240110230-A1 | BIOMARKERS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-11946094-B2 | Combination therapies and methods of use thereof | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20240091226-A1 | Forms and Formulations Of A Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitor | SUMITOMO PHARMA ONCOLOGY, INC. | 2024-03-21 | — | — | US | disclosed |
| US-20240096469-A1 | METHODS OF PREDICTING RESPONSES TO DISEASE TREATMENTS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-03-21 | — | — | US | disclosed |
| CN-117715905-A | Checkpoint kinase 1 (CHK 1) inhibitors and uses thereof | 无界生物公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20240075033-A1 | ALK5 INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROME | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2024-03-07 | — | — | US | disclosed |
| EP-4323356-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | Nuvalent, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| EP-4313052-A1 | ALK-5 INHIBITORS AND USES THEREOF | Sumitomo Pharma Oncology, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117500803-A | Amino-substituted heterocycles for the treatment of cancers with EGFR mutations | 纽威伦特公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-4301875-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-01-10 | — | — | EP | disclosed |
| US-11865123-B2 | Methods of inhibiting pathological angiogenesis | UNITY BIOTECHNOLOGY, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| CN-117355304-A | ALK-5 inhibitors and uses thereof | 住友制药肿瘤公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2024006252-A1 | DUAL INHIBITION OF MDM2 AND EIF2-ALPHA INDUCES CELL DEATH IN MULTIPLE CANCER CELL TYPES | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230414590-A1 | THERAPEUTIC SMALL MOLECULES FOR TREATMENT OF PULMONARY HYPERTENSION | THE TEXAS A&M UNIVERSITY SYSTEM | 2023-12-28 | — | — | US | disclosed |
| CN-117295825-A | Biomarkers for the treatment of cancer using MDM2 antagonists | 大冢制药株式会社 | 2023-12-26 | — | — | CN | disclosed |
| EP-4291902-A2 | BIOMARKERS FOR CANCER TREATMENT | Foundation Medicine, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230398130-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATING STEM CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-12-14 | — | — | US | disclosed |
| WO-2022221227-A9 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023230477-A1 | PYRIDINE CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023225629-A2 | METHODS OF GENERATING NATURAL KILLER CELLS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-4274567-A1 | FORMS AND FORMULATIONS OF A TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITOR | Sumitomo Pharma Oncology, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-117017987-A | Pharmaceutical composition for preventing and treating lung cancer, and preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2023-11-10 | — | — | CN | disclosed |
| CN-117017987-A | Pharmaceutical composition for preventing and treating lung cancer, and preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023215756-A2 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY VASCULAR DISEASE | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230338337-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-11795157-B2 | Tetrahydroindazoles and medical uses thereof | GENASE THERAPEUTICS B.V. (NL) | 2023-10-24 | — | — | US | disclosed |
| EP-4259145-A1 | ALK-5 INHIBITORS AND USES THEREOF | Sumitomo Pharma Oncology, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| US-11789012-B2 | Cell death biomarker | UCL BUSINESS LTD (GB) | 2023-10-17 | — | — | US | disclosed |
| US-20230313313-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-05 | — | — | US | disclosed |
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2023187599-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | DIDENKO KIRILL (MX) | 2023-10-05 | — | — | WO | disclosed |
| CN-116829143-A | Forms and formulations of non-receptor tyrosine kinase 1 (TNK 1) inhibitors | 住友制药肿瘤公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230293471-A1 | USE OF APE1/REF-1 INHIBITORS FOR TREATMENT OF RETINAL DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2023-09-21 | — | — | US | disclosed |
| US-20230285375-A1 | COMPOUNDS FOR USE IN REGULATING FOLLICLE MATURATION | AARHUS UNIVERSITET (DK) | 2023-09-14 | — | — | US | disclosed |
| US-11746103-B2 | ALK-5 inhibitors and uses thereof | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230272485-A1 | REPLICATION STRESS PATHWAY AGENT COMPOSITIONS AND METHODS FOR TREATING CANCER | BOUNDLESS BIO, INC. | 2023-08-31 | — | — | US | disclosed |
| EP-4232012-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATING STEM CELLS | Massachusetts Institute of Technology (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4234025-A2 | TREATMENT OF DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS | Unity Biotechnology, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2023158713-A1 | UNSUPERVISED MACHINE LEARNING METHODS | AMPEL BIOSOLUTIONS, LLC (US) | 2023-08-24 | — | — | WO | disclosed |
| CN-116546986-A | ALK-5 inhibitors and uses thereof | 住友制药肿瘤公司 | 2023-08-04 | — | — | CN | disclosed |
| WO-2023144332-A1 | TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS | GENASE THERAPEUTICS B.V. (NL) | 2023-08-03 | — | — | WO | disclosed |
| US-11712433-B2 | Compositions comprising PKM2 modulators and methods of treatment using the same | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| CN-116510024-A | Composition, preparation method and application thereof | 上海复东生物医药有限责任公司 | 2023-08-01 | — | — | CN | disclosed |
| US-20230233557-A1 | FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | BOUNDLESS BIO, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| EP-4204812-A2 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-07-05 | — | — | EP | disclosed |
| US-11666561-B2 | Compounds for use in regulating follicle maturation | AARHUS UNIVERSITET (DK) | 2023-06-06 | — | — | US | disclosed |
| CN-116194088-A | Biomarkers for the treatment of cancer using MDM2 antagonists | 大冢制药株式会社 | 2023-05-30 | — | — | CN | disclosed |
| US-11648226-B2 | Use of APE1/Ref-1 inhibitors for treatment of retinal diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-05-16 | — | — | US | disclosed |
| EP-3441069-B1 | TREATMENT OF DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS | UNITY BIOTECHNOLOGY INC (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-4157204-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | Buck Institute for Research on Aging (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20230090742-A1 | AMINOPYRIMIDINYLAMINOBENZONITRILE DERIVATIVES AS NEK2 INHIBITORS | SUMITOMO PHARMA ONCOLOGY, INC. | 2023-03-23 | — | — | US | disclosed |
| WO-2023039161-A1 | METHODS OF TREATING CANCER DEPENDENT ON MYC GENE EXPRESSSION | KARTOS THERAPEUTICS (US) | 2023-03-16 | — | — | WO | disclosed |
| WO-2023039160-A1 | METHODS OF TREATING A CANCER OVEREXPRESSING ONE OR MORE BCL-2 FAMILY PROTEINS | KARTOS THERAPEUTICS (US) | 2023-03-16 | — | — | WO | disclosed |
| US-11603374-B2 | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-03-14 | — | — | US | disclosed |
| EP-3344275-B1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS INC (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2023014718-A2 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR TO AMELIORIATE VASCULAR STIFFNESS | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-4129285-A1 | COMPOUNDS FOR USE IN REGULATING FOLLICLE MATURATION | Aarhus Universitet (DK) | 2023-02-08 | — | — | EP | disclosed |
| CN-109843333-B | Intermediate drug with synergistic anticancer activity and polyethylene glycol coupled synergistic anticancer drug, and preparation method and application thereof | 重庆阿普格雷生物科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20230037284-A9 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2023-02-02 | — | — | US | disclosed |
| WO-2023010102-A1 | IMIDAZO[1,2-B]PYRIDAZINYL COMPOUNDS AND USES THEREOF | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20230027472-A1 | TARGETING P73 FOR CANCERS RESISTANT TO BH3 MIMETICS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-01-26 | — | — | US | disclosed |
| US-20230026313-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2022266491-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-12-22 | — | — | WO | disclosed |
| US-11529350-B2 | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11524963-B2 | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2022-12-13 | — | — | US | disclosed |
| WO-2022251502-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| US-20220363696-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. | 2022-11-17 | — | — | US | disclosed |
| US-20220347277-A1 | Methods to Enhance Tumor Immunogenicity and Compositions for Autologous Cancer Immunotherapeutic Products Using Modified Tumor Cells and Modified Dendritic Cells | AIVITA BIOMEDICAL INC (US) | 2022-11-03 | — | — | US | disclosed |
| EP-4081801-A2 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-11484600-B2 | Intermediate drug with synergistic anticancer activity and polyethylene glycol-coupled synergistic anticancer drug, and preparation method therefor and use thereof | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2022-11-01 | — | — | US | disclosed |
| US-11478469-B2 | Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-10-25 | — | — | US | disclosed |
| WO-2022221227-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| US-11471456-B2 | Formulations comprising heterocyclic protein kinase inhibitors | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-11472802-B2 | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-11471462-B2 | Compositions and methods for detecting and treating diabetes | THE BROAD INSTITUTE, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-20220323406-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATING STEM CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-10-13 | — | — | US | disclosed |
| CN-111615514-B | Substituted pyrazolo [4,3-C ] pyridine compounds as RET kinase inhibitors | 奥瑞生物药品公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20220315563-A1 | ALK-5 INHIBITORS AND USES THEREOF | SUMITOMO PHARMA ONCOLOGY, INC. | 2022-10-06 | — | — | US | disclosed |
| WO-2022204721-A1 | ALK-5 INHIBITORS AND USES THEREOF | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| US-20220305008-A1 | TREATMENT OF CANCER HAVING GNAQ OR GNA11 GENETIC MUTATIONS WITH PROTEIN KINASE C INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2022-09-29 | — | — | US | disclosed |
| CN-115066614-A | Biomarkers for treating cancer using MDM2 antagonists | 大冢制药株式会社 | 2022-09-16 | — | — | CN | disclosed |
| WO-2022185260-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022174234-A2 | BIOMARKERS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| US-20220241316-A1 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR, IS A NOVEL SENOLYTIC | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220244244-A1 | A GENETIC PHARMACOPEIA FOR COMPREHENSIVE FUNCTIONAL PROFILING OF HUMAN CANCERS | FUNCTION ONCOLOGY, INC. | 2022-08-04 | — | — | US | disclosed |
| EP-3630106-B1 | COMPOUNDS FOR USE IN REGULATING FOLLICLE MATURATION | UNIV AARHUS (DK) | 2022-07-27 | — | — | EP | disclosed |
| WO-2022150801-A1 | FORMS AND FORMULATIONS OF A TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITOR | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| US-20220202788-A1 | FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | LOXO ONCOLOGY, INC. | 2022-06-30 | — | — | US | disclosed |
| US-20220186321-A1 | PROGNOSIS METHOD OF CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-06-16 | — | — | US | disclosed |
| WO-2022126133-A1 | ALK-5 INHIBITORS AND USES THEREOF | SUMITOMO PHARMA ONCOLOGY,INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| EP-3849986-B1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11351167-B2 | Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissue | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220162200-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. | 2022-05-26 | — | — | US | disclosed |
| WO-2022103706-A1 | THERAPEUTIC SMALL MOLECULES FOR TREATMENT OF PULMONARY HYPERTENSION | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-19 | — | — | WO | disclosed |
| EP-3994132-A1 | TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF | Sumitomo Dainippon Pharma Oncology, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| WO-2022087526-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATING STEM CELLS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20220112214-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2022-04-14 | — | — | US | disclosed |
| CN-114302878-A | Tyrosine kinase non-receptor 1(TNK1) inhibitors and uses thereof | 大日本住友制药肿瘤公司 | 2022-04-08 | — | — | CN | disclosed |
| US-20220096466-A1 | TREATMENT OF PARKINSON'S DISEASE AND OTHER CONDITIONS CAUSED OR MEDIATED BY SENESCENT ASTROCYTES USING SMALL MOLECULE SENOLYTIC AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2022-03-31 | — | — | US | disclosed |
| EP-3974424-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | Genase Therapeutics B.V. (NL) | 2022-03-30 | — | — | EP | disclosed |
| EP-3669881-B1 | COMPOSITIONS FOR USE IN THE TREATMENT OF SENESCENCE-ASSIOCATED EYE DISEASE AND DISORDERS | BUCK INST RES AGING (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20220087988-A1 | FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | LOXO ONCOLOGY, INC. | 2022-03-24 | — | — | US | disclosed |
| CN-108348571-B | Peptidomimetic macrocycles and uses thereof | 艾瑞朗医疗公司 | 2022-03-22 | — | — | CN | disclosed |
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC. | 2022-03-17 | — | — | US | disclosed |
| US-20220072015-A1 | Methods of Inhibiting Pathological Angiogenesis | UNITY BIOTECHNOLOGY, INC. | 2022-03-10 | — | — | US | disclosed |
| WO-2022043930-A2 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-03 | — | — | WO | disclosed |
| EP-3955916-A1 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR, IS A NOVEL SENOLYTIC | Buck Institute for Research on Aging (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20220040166-A1 | Methods and Compositions of Treating an Ophthalmic Condition | KARTOS THERAPEUTICS (US) | 2022-02-10 | — | — | US | disclosed |
| EP-3947736-A1 | PROGNOSIS METHOD OF CANCER | Centre national de la recherche scientifique (FR) | 2022-02-09 | — | — | EP | disclosed |
| US-20220031694-A1 | COMBINATION PRODUCT OF BCL-2 INHIBITOR AND MDM2 INHIBITOR AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-02-03 | — | — | US | disclosed |
| US-20220031694-A1 | COMBINATION PRODUCT OF BCL-2 INHIBITOR AND MDM2 INHIBITOR AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197729-A1 | ALK-5 Inhibitors and Uses Thereof | ACVR1, ALK, ACVRL1 | HRH3 2347/4885HTR2A 3822/4885HTR1A 3104/4885 |
| US-20250127777-A1 | DUAL INHIBITION OF MDM2 AND EIF2-ALPHA INDUCES CELL DEATH IN MULTIPLE CANCER CELL TYPES | EIF2AK1, EIF2AK2, EEF2K | HRH3 4326/4885HTR2A 3747/4885HTR1A 4648/4885 |
| US-20240293364-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | MSH2, MRE11, RAD50 | HRH3 716/4885HTR2A 1352/4885HTR1A 1772/4885 |
| US-11963957-B2 | Treating cardiovascular disease by selectively eliminating senescent cells | GLA, MMP13, MMP11 | HRH3 4602/4885HTR2A 4293/4885HTR1A 4414/4885 |
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | JAK2, JAK1, MPL | HRH3 2961/4885HTR2A 4274/4885HTR1A 4108/4885 |
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | RAB5IF, CLTB, TBK1 | HRH3 3911/4885HTR2A 4787/4885HTR1A 4851/4885 |
| US-20220072015-A1 | Methods of Inhibiting Pathological Angiogenesis | VEGFA, FLT1, FLT4 | HRH3 2828/4885HTR2A 3669/4885HTR1A 3335/4885 |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | EGFR, ERBB2, ERBB3 | HRH3 1550/4885HTR2A 1269/4885HTR1A 1492/4885 |
| US-20230313313-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | SKP2, MDM2, TP53 | HRH3 3521/4885HTR2A 3607/4885HTR1A 3957/4885 |
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | CHEK1, CHEK2, RAD1 | HRH3 2078/4885HTR2A 4678/4885HTR1A 4522/4885 |
| US-11484600-B2 | Intermediate drug with synergistic anticancer activity and polyethylene glycol-coupled synergistic anticancer drug, and preparation method therefor and use thereof | WEE1, WEE2, SLC11A2 | HRH3 4761/4885HTR2A 4795/4885HTR1A 4464/4885 |
| US-20220202788-A1 | FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | RET, ALK, BRAF | HRH3 355/4885HTR2A 706/4885HTR1A 505/4885 |
| US-12115153-B2 | Methods of treating cancer | VHL, MDM2, TP53 | HRH3 4256/4885HTR2A 4248/4885HTR1A 4181/4885 |
| US-11529350-B2 | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | TNK1, TNNI3K, TYK2 | HRH3 627/4885HTR2A 1903/4885HTR1A 969/4885 |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | CHEK1, CHEK2, RAD1 | HRH3 2078/4885HTR2A 4678/4885HTR1A 4522/4885 |
| US-11865123-B2 | Methods of inhibiting pathological angiogenesis | VEGFA, FLT1, FLT4 | HRH3 2828/4885HTR2A 3669/4885HTR1A 3335/4885 |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | JAK2, JAK1, PDPK1 | HRH3 2932/4885HTR2A 3698/4885HTR1A 3702/4885 |
| US-11980616-B2 | Treating liver disease by selectively eliminating senescent cells | GLA, MMP13, MMP11 | HRH3 4349/4885HTR2A 4480/4885HTR1A 4542/4885 |
| US-20250288572-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY VASCULAR DISEASE | GLUL, GGT1, GLS | HRH3 4459/4885HTR2A 4832/4885HTR1A 4453/4885 |
| US-20230090742-A1 | AMINOPYRIMIDINYLAMINOBENZONITRILE DERIVATIVES AS NEK2 INHIBITORS | NEK4, NEK2, NEK1 | HRH3 1470/4885HTR2A 3724/4885HTR1A 4550/4885 |
| US-11712433-B2 | Compositions comprising PKM2 modulators and methods of treatment using the same | PDK1, PDK2, PKM | HRH3 4705/4885HTR2A 4267/4885HTR1A 4586/4885 |
| US-20240299558-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | BCL3, MCL1, BCL2 | HRH3 3817/4885HTR2A 3269/4885HTR1A 4409/4885 |
| US-20220087988-A1 | FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | RET, ALK, BRAF | HRH3 355/4885HTR2A 706/4885HTR1A 505/4885 |
| US-20220162200-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PKM, PDK2 | HRH3 3433/4885HTR2A 2472/4885HTR1A 2645/4885 |
| US-11963950-B2 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | RET, ALK, BRAF | HRH3 355/4885HTR2A 706/4885HTR1A 505/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | HRH3 3343/4885HTR2A 4075/4885HTR1A 4080/4885 |
| US-20220096466-A1 | TREATMENT OF PARKINSON'S DISEASE AND OTHER CONDITIONS CAUSED OR MEDIATED BY SENESCENT ASTROCYTES USING SMALL MOLECULE SENOLYTIC AGENTS | SNCA, SENP3, SENP2 | HRH3 3134/4885HTR2A 1430/4885HTR1A 2455/4885 |
| US-20250134876-A1 | METHODS OF TREATING A CANCER OVEREXPRESSING ONE OR MORE BCL-2 FAMILY PROTEINS | BCL2, BCL2L2, BCL2L1 | HRH3 4603/4885HTR2A 2325/4885HTR1A 3858/4885 |
| US-12595515-B2 | Prognosis method of cancer | DDIT3, UPF1, MKI67 | HRH3 4795/4885HTR2A 3403/4885HTR1A 3607/4885 |
| US-20250090517-A1 | Methods of Treating Cancer | VHL, MDM2, TP53 | HRH3 4256/4885HTR2A 4248/4885HTR1A 4181/4885 |
| US-12599592-B2 | Therapeutic small molecules for treatment of pulmonary hypertension | GSTP1, GSTK1, GSTM1 | HRH3 1200/4885HTR2A 3114/4885HTR1A 2519/4885 |
| US-20230338337-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | IRF2BP2, BST2, IRF3 | HRH3 2783/4885HTR2A 2491/4885HTR1A 2882/4885 |
| US-20230037284-A9 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | BID, FLT3, GRPR | HRH3 2900/4885HTR2A 2693/4885HTR1A 4027/4885 |
| US-20230233557-A1 | FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS | PIM1, GK, PIM2 | HRH3 3094/4885HTR2A 4302/4885HTR1A 4598/4885 |
| US-20250388602-A1 | Tetrahydropyranopyrazole Derivatives for the Treatment of Cancer and Viral Infections | CCNA1, KRAS, RSU1 | HRH3 1076/4885HTR2A 4497/4885HTR1A 1713/4885 |
| US-11524963-B2 | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors | RET, ROR1, BRAF | HRH3 955/4885HTR2A 2939/4885HTR1A 2235/4885 |
| US-11471456-B2 | Formulations comprising heterocyclic protein kinase inhibitors | PIM1, GK, PIM2 | HRH3 3094/4885HTR2A 4302/4885HTR1A 4598/4885 |
| US-20220112214-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, FRK | HRH3 1245/4885HTR2A 2162/4885HTR1A 2144/4885 |
| US-20250134877-A1 | METHODS OF TREATING CANCER DEPENDENT ON MYC GENE EXPRESSSION | MYC, MYCBP, TP53 | HRH3 4298/4885HTR2A 3258/4885HTR1A 3735/4885 |
| US-20230026313-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | CHEK1, CHEK2, RAD1 | HRH3 2078/4885HTR2A 4678/4885HTR1A 4522/4885 |
| US-11964988-B2 | Fused heterocyclic compounds as RET kinase inhibitors | RET, ROR1, FRK | HRH3 1245/4885HTR2A 2162/4885HTR1A 2144/4885 |
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | DAGLA, DAGLB, MGLL | HRH3 3816/4885HTR2A 1756/4885HTR1A 2289/4885 |
| US-12527790-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | CHEK1, RAD1, CHEK2 | HRH3 624/4885HTR2A 3868/4885HTR1A 2490/4885 |
| US-20240075033-A1 | ALK5 INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROME | ALK, ALKBH5, ALKBH3 | HRH3 1578/4885HTR2A 3084/4885HTR1A 3098/4885 |
| US-20220363696-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | EGFR, ERBB2, ERBB4 | HRH3 562/4885HTR2A 692/4885HTR1A 1021/4885 |
| US-20220315563-A1 | ALK-5 INHIBITORS AND USES THEREOF | ACVR1, ALK, ACVRL1 | HRH3 2119/4885HTR2A 3860/4885HTR1A 3125/4885 |
| US-20220031694-A1 | COMBINATION PRODUCT OF BCL-2 INHIBITOR AND MDM2 INHIBITOR AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | BCL2, BCL2L2, BCL2L1 | HRH3 4693/4885HTR2A 1915/4885HTR1A 3840/4885 |
| US-12138250-B2 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | RET, ALK, BRAF | HRH3 355/4885HTR2A 706/4885HTR1A 505/4885 |
| US-20230414590-A1 | THERAPEUTIC SMALL MOLECULES FOR TREATMENT OF PULMONARY HYPERTENSION | GSTP1, GSTK1, GSTM1 | HRH3 2475/4885HTR2A 4428/4885HTR1A 4043/4885 |
| US-11471462-B2 | Compositions and methods for detecting and treating diabetes | SLC2A2, SLC2A1, SLC5A2 | HRH3 4000/4885HTR2A 1648/4885HTR1A 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.